OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Rentschler Biopharma Takes First Steps in US Expansion Project
Rentshler Biopharma has begun its expansion project in the United States by putting a single-use bioreactor into operation at the Milford facility in Massachusetts.
Rentshler Biopharma, a contract development and manufacturing organization (CDMO) headquartered in Germany, has begun its expansion project in the United States by putting a single-use bioreactor into operation at the Milford facility in Massachusetts.
In a Nov. 6, 2019 press release, the company announced that the XDR-500 bioreactor, which has a working volume of 100–500 L and downstream capabilities of 2–8 g/L, will be part of the good manufacturing practice (GMP) facility suite concept. The company anticipates that the system will be ready for clients by mid-2020, and it is currently being prepared for technology transfer.
Additionally, Rentshler Biopharma revealed some other expansion plans, including another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing and will feature lab capacity for new modalities. Through its client-centric approach, the company aims to facilitate robust and scalable production of complex biomolecules in both Europe and the US.